Skip to content

The Effect of Bupivacaine Liposome on Perioperative Inflammatory Pain and Neurocognitive Function in Knee Arthroplasty

The Effect of Bupivacaine Liposome on Perioperative Inflammatory Pain and Neurocognitive Function in Knee Arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114897
Enrollment
Unknown
Registered
2025-12-18
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee joint diseases

Interventions

Ropivacaine group:Adductor canal block was performed using ropivacaine
Bupivacaine liposome group:Adductor duct block was performed using bupivacaine liposomes

Sponsors

The First Affiliated Hospital of University of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients scheduled for elective unilateral knee arthroplasty; 2.Aged 18–90 years, regardless of gender; 3.BMI: 18–30 kg/m^2; 4.ASA classification of II–IV; 5.Able to comprehend and perform assessments such as the Visual Analogue Scale (VAS) and the Confusion Assessment Method (CAM) for delirium scoring; 6.Voluntarily sign the informed consent form and agree to comply with the requirements of the study protocol.

Exclusion criteria

Exclusion criteria: 1.Severe cardiac, pulmonary, hepatic, or renal dysfunction; 2.History of psychiatric disorders or long-term use of psychotropic medications (e.g., dementia, schizophrenia), chronic analgesic use, or history of alcohol abuse; 3.Preoperative Mini-Mental State Examination (MMSE) score < 21, indicating moderate to severe cognitive impairment; 4.History of any cerebrovascular accident within the past 3 months, such as stroke or transient ischemic attack; 5. Patients with severe infections; 6. Preoperative PaO2 < 60 mmHg or SpO2 < 92%; 7. Participation in another drug clinical trial within the past 30 days; 8. Allergy to the investigational drug.

Design outcomes

Primary

MeasureTime frame
VAS score;

Secondary

MeasureTime frame
CAM Scale;Assessment of joint motor function;TNF-a;IL-1ß;IL-10;

Countries

China

Contacts

Public ContactXu Min

The First Affiliated Hospital of University of Science and Technology of China

seumexumin@163.com+86 138 5690 4576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026